PARP

News

XinThera buy builds Gilead’s cancer, inflammation pipeline

Gilead Sciences has bulked up its early-stage R&D portfolio with an agreement to buy XinThera, adding drugs targeting PARP for oncology and MK2 for inflammatory diseas

News

Lynparza under siege in first-line prostate cancer

New data from Pfizer and J&J encroach on AZ and Merck's territory with the PARP inhibitor.

Events

Partner Content

PARP & DDR Inhibitors Summit 2021

Optimize PARP inhibitors in the clinic

News

AZ/MSD’s PARP inhibitor shows promise as first-line ovarian ...

AstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this time in first-line treatment of advanced ovarian cancer.

News

Merck and Pfizer stop third Bavencio ovarian cancer trial

Merck and Pfizer are discontinuing the Phase III JAVELIN Ovarian PARP 100 study evaluating Bavencio (avelumab) in advanced ovarian cancer, signalling yet more disappointment for the PD-L1 immuno

News